FDA Approves First Oral PCSK9 Inhibitor for Hypercholesterolemia

The Food and Drug Administration has approved Lipfendra (enlicitide) for the treatment of hypercholesterolemia and heterozygous familial hypercholesterolemia. This marks the first regulatory approval of a PCSK9 inhibitor formulated as an oral daily pill. The drug is indicated for use in conjunction with dietary interventions and physical activity.

Approval follows clinical trial data demonstrating that the medication reduces low-density lipoprotein (LDL) cholesterol levels by approximately 56% to 59%. The trials involved 3,207 adult participants who were already receiving maximum tolerated statin therapy. The mechanism of action involves binding to PCSK9 proteins to prevent the degradation of LDL receptors in the liver.

This development introduces a non-invasive alternative to existing treatments, such as lipoprotein apheresis, which requires blood filtration. The availability of an oral therapeutic may improve patient adherence and reduce the reliance on more complex, invasive clinical procedures for managing genetically driven cardiovascular risk factors.